Introduction
============

The efficacy of antiretroviral therapy (ART) has improved significantly within the recent years and has subsequently led to normal life expectancy in human immunodeficiency virus (HIV)-positive patients.[@b1-ppa-11-1897]--[@b4-ppa-11-1897] Adherence to ART is crucial to overall treatment success.[@b5-ppa-11-1897]--[@b9-ppa-11-1897] Yet, evaluation of adherence remains challenging. In addition to medication event monitoring systems (MEMSs), self-reports of adherence have been studied.[@b7-ppa-11-1897],[@b10-ppa-11-1897]--[@b13-ppa-11-1897] Adherence questionnaires have been evaluated for clinical use.[@b14-ppa-11-1897]--[@b16-ppa-11-1897] These questionnaires offer the opportunity to assess adherence and, importantly, the reasons for adherence problems. Adherence is known to be a complex behavior influenced by many factors, such as sociocultural background, comorbidities, and HIV- and ART-related factors.[@b17-ppa-11-1897],[@b18-ppa-11-1897] Due to pharmacological improvements, drugs with lower dosing frequencies and side effects, as well as single-tablet regimens (STRs), have been developed and have rendered drug use less cumbersome for patients.[@b6-ppa-11-1897],[@b19-ppa-11-1897]--[@b21-ppa-11-1897] Furthermore, the prevalence of nonadherence and the reasons for nonadherent behaviors may have changed over time, due to sociocultural progress. Therefore, it is unclear whether the results from earlier studies are applicable to the current treatment of patients.

To examine the complex influences of adherence currently, we analyzed the frequency of nonadherence, the patient-, HIV-, and ART-related factors associated with nonadherence, and patients' reasons for nonadherent behaviors in a large German HIV patient study group. To achieve a balanced distribution between adherent and non-adherent patients, disproportionately more participants with suspected adherence problems were subsequently included in the study group.

Patients and methods
====================

Study design and patients
-------------------------

The study was a qualitative and quantitative, cross-sectional, noninterventional, multicenter clinical trial. Physicians (n=10) enrolled HIV-infected individuals aged 18 years and older, from September 2014 to April 2015 at four German centers (three primary care centers and one university hospital). Patients not receiving ART or those undergoing treatment for less than 6 months with still detectable viral loads (VLs) were excluded. Because of the expected low prevalence of nonadherence in Germany, recruitment of patients was not unselected; physicians were asked to enhance recruitment of patients with suspected nonadherence, thus ensuring a sufficient sample size of patients with adherence problems.

This study was officially approved by the ethics committee of the University Hospital Klinikum rechts der Isar of the Technical University of Munich, Germany (approval number 240/14). This study was performed according to the Declaration of Helsinki. The study objectives and protocol were explained by the study personnel to the patients. Written informed consent was obtained from all participants before including them in the study. This study was not registered because of the noninterventional and cross-sectional study design.

Adherence questionnaires
------------------------

Adherence questionnaires were provided to physicians and patients. The physician's questionnaire contained questions regarding biomedical issues: time since HIV diagnosis, ART duration, current ART regimen, HIV transmission route, history of acquired immune deficiency syndrome (AIDS), comorbidities, co-medication, HIV-1 RNA VL, and CD4 cell count. The questionnaire was used to evaluate patient-, HIV-, and ART-related factors associated with nonadherence. Furthermore, the physicians were asked to classify their patients based on current and past adherence to one of the three adherence groups: A, good adherence; B, unstable adherence; C, poor adherence. Patients with excellent history of adherence were classified as patients with "good adherence." Patients with intermittent phases of nonadherence were classified as patients with "unstable adherence." Finally, patients who could rarely adhere were classified as patients with poor adherence. Information on patients' age and sex was extracted from their medical records.

The patients' questionnaire was based on the German SMAQ MASRI Hybrid,[@b22-ppa-11-1897] which is a validated questionnaire.[@b14-ppa-11-1897],[@b15-ppa-11-1897] The patients' questionnaire included questions regarding the frequency and extent of nonadherence in three different time frames. In addition, it contained a list of reasons for nonadherent behavior, which was developed by our research group, as well as items regarding satisfaction with ART. Detailed information about the patient items is provided in [Table 1](#t1-ppa-11-1897){ref-type="table"}. All questionnaires were prepared in the German language. The items were categorized, and some were renamed. For this study, items were translated into English.

Study end points
----------------

The outcomes of interest were as follows: Concordance between physicians' adherence assessment and patients' self-reports of adherence, and its association with viral suppression.Frequency and extent of nonadherent behavior in different time frames.Patient-, HIV-, and ART-related factors associated with nonadherence based on physicians' adherence assessment.Patients' self-reported reasons for nonadherent behavior and self-reported satisfaction with ART.

Statistical analyses
--------------------

All results were expressed either in median and interquartile range (IQR), in number and percentage, or as odds ratio (OR) and 95% confidence interval (95% CI). First, the study population was characterized by describing sex, age, route of HIV transmission, history of AIDS, comorbidities, co-medication, time since HIV diagnosis, VL, CD4 cell count, current ART regimen, current ART dosing, and ART duration. Second, the concordance between physicians' adherence assessment and patients' self-reports of adherence was evaluated. We examined concordance between the categories "good adherence" in the physicians' assessment and "no missed dose during the last week" in the patients' questionnaire, as well as between "reduced adherence" (defined as unstable or poor adherence) and "one or more missed doses during the last week." All the previously mentioned concordant pairs were summed to describe the overall concordance of adherence assessment by physicians and patients. In addition, the association of physicians' adherence assessment with viral suppression (\<200 cp/mL vs ≥200 cp/mL) was calculated. The Cohen's *κ* test was used to measure agreement between physicians' adherence assessment and patients' self-reports of adherence and between physicians' adherence assessment and suppression of VL. Third, univariate descriptive analyses were conducted to compare patient-, HIV-, and ART-related factors between the three adherence groups: A, good vs B, unstable vs C, poor adherence. Medians were analyzed using the Kruskal--Wallis test, and percentages using the Fisher's extended exact test (Freeman--Halton test). In addition, binary multivariate logistic regression analyses were conducted using stepwise backward selection to assess the relationship between patient-, HIV-, and ART-related factors and "reduced adherence" (defined as unstable or poor). Covariates included in the logistic regression models were as follows: sex, age, route of HIV transmission, history of AIDS, comorbidities, co-medication, time since HIV diagnosis, and ART duration. Current ART regimen, VL, and CD4 cell count were not included in the model, because they were expected to be consequences of reduced adherence rather than causes for nonadherence and, therefore, constituted no proper variables for the model. We used stepwise backward selection until only variables with *p*\<0.05 remained in the model. OR and 95% CI were reported for those covariates. In order to study patients' beliefs, the patients' self-reported reasons for nonadherent behavior were analyzed. After a general description of the reasons for nonadherent behavior, the frequency between the three groups was compared to focus on the barriers to adherence for patients with unstable or poor adherence. Finally, satisfaction with ART, pertaining to its interference with daily routine, efficacy, simplicity, and side effects, was examined. In all analyses, a *p*-value \<0.05 was considered to be statistically significant. All statistical analyses were conducted using IBM SPSS Statistics Version 23 (IBM Corporation, Armonk, NY, USA).

Results
=======

Study population and adherence groups
-------------------------------------

A total of 220 patients were enrolled at four German study centers. Due to protocol violation, five patients were excluded: one patient because of ART interruption, and the remaining four because of persistent detection of VLs despite ART duration for less than 6 months ([Figure 1](#f1-ppa-11-1897){ref-type="fig"}).

Therefore, 215 HIV-positive adults were included in the analyses: 80% were male, and the median age was 47 years (IQR 37--54). Additional characteristics of the study population are summarized in [Table 2](#t2-ppa-11-1897){ref-type="table"}.

The physicians' adherence assessment between the three adherence groups showed the following: 75% (162/215) in group A (good adherence), 17% (36/215) in group B (unstable adherence), and 8% (17/215) in group C (poor adherence).

Concordance of physicians' adherence assessment with patients' self-reports of adherence and its association with viral suppression
-----------------------------------------------------------------------------------------------------------------------------------

The adherence of 162 patients was described as good by their physicians. Of those patients, 90% (n=145) reported "no dose missed during the last week," while 10% (n=17) reported "one or more doses missed during the last week." The adherence of 53 patients was described as "reduced" (unstable, n=36; poor, n=17). Of those patients, 48% (n=25) reported "no dose missed during the last week," while 52% (n=27) reported "one or more missed doses during the last week;" one answer was missing. Of all patients, 68% (n=145) were assessed by both physicians and themselves as adherent, while 13% of all patients (n=27) were assessed by both physicians and themselves as nonadherent. Therefore, concordance of physicians' adherence assessment and patients' self-reports of adherence was 81%. All numbers are provided in [Table 3](#t3-ppa-11-1897){ref-type="table"}. The *κ* value for agreement was −0.090.

Of the 162 patients with good adherence, 99% (n=160) had a VL \<200 cp/mL, while 1.2% (n=2) had a VL ≥200 cp/mL. Of the 53 patients with reduced adherence, 70% (n=37) had a VL \<200 cp/mL, while 30% (n=16) had a VL ≥200 cp/mL. Seventy-four percent of all patients (n=160) were described by physicians as adherent and had a VL \<200 cp/mL, while 7.4% of all patients (n=16) were described by physicians as nonadherent and had a VL ≥200 cp/mL. The *κ* value for agreement was 0.372.

Differences in patients' self-reports of adherence in relation to the evaluated time frame
------------------------------------------------------------------------------------------

Concurrent with results from physicians' assessment regarding reduced adherence, a higher percentage of patients in groups B and C reported missing doses in all three time frames: regarding the doses missed during the last month, a higher percentage of patients from groups B and C reported "missed one or more doses per week" (A: 2.5% \[4/162\] vs B: 8.3% \[3/36\] vs C: 24% \[4/17\], *p*\<0.001). Regarding the doses missed during the last week, an even higher percentage of patients from groups B and C reported "missed one or more doses" (A: 11% \[17/162\] vs B: 47% \[17/36\] vs C: 63% \[10/17\], *p*\<0.001). Regarding the doses missed during the last weekend, the percentage of patients from groups B and C who reported "one or more missed doses" was still significantly high (A: 3.1% \[5/162\] vs B: 22% \[8/36\] vs C: 31% \[5/17\], *p*\<0.001).

Factors associated with reduced adherence
-----------------------------------------

[Table 4](#t4-ppa-11-1897){ref-type="table"} summarizes the patient-, HIV-, and ART-related factors in the three adherence groups. Significant differences between the three groups regarding the following patient-related factors are: age, HIV transmission route, chronic hepatitis C infection (HCV), and psychiatric disorders. Furthermore, [Table 4](#t4-ppa-11-1897){ref-type="table"} summarizes the significant differences between the groups regarding the following HIV- and ART-related factors: time since HIV diagnosis, history of AIDS, VL, CD4 cell count, ART duration, and current ART regimen. Sex, co-medication, and dosing frequency did not show significant differences between groups.

Multivariate regression analysis showed that the following variables remained significantly associated with reduced adherence, defined as unstable or poor: age \<30 years (OR =4.2, 95% CI 1.4--12.6, *p*=0.010), HIV transmission via intravenous drug use (IVDU; OR =16.7, 95% CI 4.2--66.2, *p*\<0.001), history of AIDS (OR =5.8, 95% CI 2.2--15.3, *p*\<0.001), and psychiatric disorders (OR =2.5, 95% CI 1.2--5.4, *p*=0.015).

Self-reported reasons for nonadherent behavior
----------------------------------------------

A higher proportion of patients from adherence groups B and C than from group A reported reasons for adherence problems (A: 32% \[52/162\] vs B: 78% \[24/36\] vs C: 94% \[16/17\], *p*\<0.001). In general, the most frequently reported reasons were as follows: just forgot (n=16), reminder of the disease (n=16), skipping medication when feeling bad (n=13), stress/stressful work (n=12), interactive toxicity beliefs regarding alcohol or party drugs/going out (n=12), different daily routine (n=10), and afraid of being seen (n=10). "Skipping medication when feeling bad," "reminder of the disease," "interactive toxicity beliefs regarding alcohol or party drugs/going out," "too high a dose," "afraid of being seen," "no need of undergoing ART anymore," and "financial constraints" were the reasons reported significantly more often by groups B and C patients than by the group A patients, as shown in [Figure 2](#f2-ppa-11-1897){ref-type="fig"}.

Patient satisfaction with ART and its association with adherence
----------------------------------------------------------------

A higher percentage of patients from adherence groups B and C reported that they were not satisfied with ART regarding interference with daily routine, efficacy, simplicity, and side effects. While dissatisfaction regarding interference with daily routine, efficacy, and simplicity was significantly associated with unstable and poor adherence, dissatisfaction regarding side effects was not significantly associated with unstable or poor adherence, as summarized in [Table 5](#t5-ppa-11-1897){ref-type="table"}.

A higher percentage of patients from groups B and C agreed having problems with adherence (A: 8.6% \[14/162\] vs B: 14% \[5/35\] vs C: 35% \[6/17\], *p*=0.008). Recognized problems included: aversion to pill swallowing (n=3), side effects (n=4), irregular daily routine (n=1), negligence (n=1), and problems with dietary restrictions (n=1). A lower percentage of patients from groups B and C rated the importance of regular intake of medication as very high (A: 83% \[133/162\] vs B: 66% \[23/36\] vs C: 71% \[12/17\], *p*=0.033).

Discussion
==========

This cross-sectional study provides insights into the factors associated with a higher risk of nonadherence and into the self-reported reasons for nonadherence. Physicians correlate extensive information, including the frequency of nonadherence and reasons for nonadherent behavior, that are collected over a long time during patient interviews, with patients' VL.[@b23-ppa-11-1897]--[@b25-ppa-11-1897] This provides a long-term, multidimensional overview of adherence. Therefore, physicians' adherence assessment was used to classify adherence groups, although this may be subjective. In our study, physicians' adherence assessment and patients' self-reports of missed doses showed good concordance. In addition, there was a strong association of physicians' adherence assessment with patients' viral suppression. However, the *κ* values estimating the agreement between the various methods of adherence assessment were poor, especially for agreement between physicians' adherence assessment and self-report, which is consistent with previous reports.[@b25-ppa-11-1897] The poor *κ* values seem to be mainly due to the disagreement in the nonadherence assessment. Of note, the *κ* statistics may be affected by the lack of symmetry and by imbalances in the marginal totals of the 2×2 tables and therefore may not be the appropriate measurement for interrater agreement in this situation.[@b26-ppa-11-1897] The disagreement in the nonadherence assessment may be due to patients' overestimation of adherence,[@b11-ppa-11-1897],[@b12-ppa-11-1897],[@b27-ppa-11-1897] alternate phases of high and low adherence, or erroneous physicians' adherence assessment. The analysis of patients' self-reports of adherence showed that the number of missed doses during the last week was higher in the self-reports of "last week" than in the ones of "last month." Therefore, we hypothesized the self-reports of last week were more accurate, probably due to recall bias.

Consistent with previous studies,[@b28-ppa-11-1897],[@b29-ppa-11-1897] the majority of included patients was adherent; however, we revealed a remarkable number of nonadherent patients in our study. Because our study aimed at including more patients with adherence problems, the frequency of nonadherence in our cohort does not represent the overall HIV population in Germany.

Our multivariate analyses demonstrated that reduced adherence was associated with known patient-related factors such as younger age,[@b5-ppa-11-1897],[@b13-ppa-11-1897],[@b30-ppa-11-1897]--[@b32-ppa-11-1897] history of hard drug use,[@b1-ppa-11-1897],[@b6-ppa-11-1897],[@b31-ppa-11-1897],[@b33-ppa-11-1897]--[@b36-ppa-11-1897] and psychiatric disorders (especially depression).[@b27-ppa-11-1897],[@b37-ppa-11-1897]--[@b43-ppa-11-1897] Our study also revealed a correlation between the history of AIDS and reduced adherence. This is probably due to the physicians' adherence assessment that included the patients' entire history over a long period of time. In accordance with various studies, our study did not find a correlation between female individuals and reduced adherence.[@b5-ppa-11-1897],[@b31-ppa-11-1897],[@b34-ppa-11-1897],[@b44-ppa-11-1897]

In line with the studies by Langness et al[@b19-ppa-11-1897] and Saberi et al,[@b46-ppa-11-1897] dissatisfaction with regimen complexity and interference with daily routine was associated with unstable or poor adherence in our study. In contrast, patient dissatisfaction with side effects was not significantly associated with unstable or poor adherence. Therefore, due to lower dosing frequencies and less side effects, it remains unclear whether pharmaceutical reasons for nonadherence are still as important as they used to be.

In addition to studying patient-, HIV-, and ART-related factors, we further analyzed the patients' reasons for non-adherent behavior. We hypothesized that there may be an association of unstable or poor adherence with patients' beliefs. Patients' beliefs are found to be crucial to adherence intervention strategies because they are reported to be frequent among patients and may be targeted to enhance adherence -- in contrast to most patient-, HIV-, and ART-related factors.[@b27-ppa-11-1897],[@b45-ppa-11-1897]

In this study, patients reported a vast variety of reasons for nonadherence. We focused on the reasons given by patients with unstable or poor adherence and found that those patients reported unspecific answers, such as just forgot or stress/stressful work, less frequently than patients with good adherence. We found a correlation between unstable or poor adherence and questioning ART efficacy and correct dosage, in agreement with Saberi et al.[@b46-ppa-11-1897] We also found that unstable or poor adherence correlated with "interactive toxicity beliefs regarding alcohol or party drugs/going out." It has already been observed that patients may intentionally skip ART doses when they consume alcohol or drugs.[@b47-ppa-11-1897]--[@b51-ppa-11-1897] It is a common misperception that alcohol inhibits ART's effectiveness and that there are potential toxic interactions between ART and alcohol consumption.[@b47-ppa-11-1897]--[@b49-ppa-11-1897] Probably, physicians avoid talking about the alcohol--ART interaction or even tell their patients not to take alcohol with their ART.[@b47-ppa-11-1897],[@b49-ppa-11-1897],[@b51-ppa-11-1897] A discussion to clarify the interaction between ART and alcohol, and other recreational drugs, may be highly beneficial to maximize adherence.

There are several limitations to our study. Although we encouraged participation of nonadherent patients, we could not include as many as expected. The sample of patients with poor adherence was especially small, due to low prevalence of nonadherence and to little motivation of those patients to participate in a study. Even though the physicians' assessment offers a relevant view of adherence, such assessments are not free from personal biases and may be influenced by VL results. Furthermore, self-reported nonadherence and reasons for nonadherence may be underreported due to poor recall and social desirability bias. No detailed information about recent alcohol consumption and hard drug use was collected in our study because we assumed that this information will be strongly underreported. Because this is an observational, cross-sectional study, no causal conclusions can be drawn and one should be cautious when generalizing these results to the overall German HIV population.

Conclusion
==========

A remarkable number of patients with unstable or poor adherence were identified in our study. In every case, physicians should evaluate patients' adherence during a short time frame to reduce recall bias. While recognition of factors associated with nonadherence helps identifying patients with a higher risk of nonadherence, it is more important to address patients' individual reasons for nonadherent behavior, such as interactive toxicity beliefs, HIV stigma, and concerns about drug dosage. In nonadherent patients, specific reasons for nonadherent behaviors are common and may be targeted for interference, thus representing potential starting points for focused counseling and adherence interventions. Further investigation is required to reveal how to optimize patient--health care provider relationships and how to unveil and solve adherence problems, thus achieving long-term viral suppression and avoiding disease progression.
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![Flowchart of the process of patients' inclusion and categorization into adherence groups A, B, and C (good, unstable, or poor adherence, respectively), based on physicians' adherence assessment.](ppa-11-1897Fig1){#f1-ppa-11-1897}

![Differences in self-reported reasons for nonadherent behavior between the adherence groups.\
**Note:** *p*-values were calculated using the Fisher's extended exact test.\
**Abbreviation:** ART, antiretroviral therapy.](ppa-11-1897Fig2){#f2-ppa-11-1897}

###### 

List of items in the patients' questionnaire

  Categorized items                                                                Answers                                                                         Original text if renamed
  -------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  **Number of missed doses**                                                                                                                                       **Frequency of forgetting medication**
  During the last month                                                            Less than 1 dose a month, 2--3 doses a month, 1--2 doses a week, nearly daily   Less than once a month, 2--3 times a month, 1--2 times a week, nearly daily
  During the last week                                                             No dose, 1 dose, 2 or more doses                                                Never, once, twice, more than two times
  During the last weekend                                                          No dose, 1 dose, 2 doses                                                        Never, once, twice
  **Reasons for nonadherent behavior**                                                                                                                             
  Skipping medication when feeling bad                                                                                                                             
  Interactive toxicity beliefs regarding alcohol or party drugs/going out          Yes/no                                                                          I want to go out. I think my medication is not compatible with alcohol/party drugs
  Reminder of the disease                                                                                                                                          Taking ART reminds me of my disease
  No need of undergoing ART anymore                                                                                                                                It does not make sense anymore
  Harmfulness of ART                                                                                                                                               The medication is harmful to me
  Nonexistence of HIV; just exists for the pharmaceutical industry to earn money                                                                                   HIV does not exist; the pharmaceutical industry just wants to earn money
  Afraid of being seen                                                                                                                                             I am afraid that others will see me taking my medication
  Too high a dose                                                                                                                                                  I think the dose is too high
  Financial constraints                                                                                                                                            Co-payment is sometimes too expensive/other financial reasons
  Other reasons                                                                    Free text field                                                                 
  **Satisfaction with ART regarding**                                                                                                                              
  Interference with daily routine                                                  Satisfied, not satisfied                                                        Ordinal scale: 1--7; 1--2: satisfied, 3--7: not satisfied
  Efficacy                                                                                                                                                         
  Simplicity                                                                                                                                                       Simplicity and acceptability
  Side effects                                                                                                                                                     
  **Other questions**                                                                                                                                              
  Importance of regular ART intake                                                 None/little, high, very high                                                    None, little, high, very high
  Problems with adherence                                                          Yes/no, free text field                                                         

**Note:** List of categorized items from the patients' questionnaire, containing also the possible answers and the original text if the items or answers were renamed.

**Abbreviations:** ART, antiretroviral therapy; HIV, human immunodeficiency virus.

###### 

Overview of the characteristics of the participants included in the analyses, with patient-, HIV-, and ART-related factors

  Items                               n     \%    Median (IQR)
  ----------------------------------- ----- ----- ----------------
  Patient-related factors                         
   Male sex                           172   80    
   Age (years)                                    47 (37--54)
   HIV transmission route                         
    MSM                               108   50    
    Origin of HPC                     29    14    
    IVDU                              15    7.0   
    Other                             27    13    
    Unknown                           39    18    
   Comorbidities                      161   75    
    Psychiatric disorder              63    29    
     Depression                       40    19    
    HBV                               10    4.7   
    HCV                               13    6.0   
    Cardiovascular risk factors       51    24    
    Major vascular event              11    5.1   
    Other                             108   50    
   Co-medication                      93    43    
    Psychiatric co-medication         24    11    
    Cardiovascular co-medication      50    23    
    Antiinfectives                    16    7.4   
   Other                              48    22    
  HIV-related factors                             
   Time since HIV diagnosis (years)               9 (4--18)
   History of AIDS                    24    11    
   HIV-1 RNA VL (cp/mL)                           19 (19--49)
   CD4 cells (n/μL)                               607 (410--850)
  ART-related factors                             
   ART duration (years)                           6 (3--14)
   ART dosing and pill burden                     
    STR                               65    30    
    MTR once daily                    103   48    
    MTR twice daily                   47    22    
   Current ART regimen                            
    NRTI containing                   192   89    
    NNRTI containing                  90    42    
    PI containing                     75    35    
    CCR5 containing                   2     0.9   
    INI containing                    69    32    

**Abbreviations:** AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; CCR5, C-C chemokine receptor 5 inhibitor; cp, copies; HBV, chronic hepatitis B infection; HCV, chronic hepatitis C infection; HIV, human immunodeficiency virus; HPC, high prevalence country; IQR, interquartile range; INI, integrase inhibitor; IVDU, intravenous drug use; MSM, men having sex with men; MTR, multi-tablet regimen; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STR, single-tablet regimen; VL, viral load.

###### 

Concordance of physicians' adherence assessment and patients' self-reports

  -----------------------------------------------------------------------------------------------------------------------------------------
                                                           Physicians' adherence assessment, n\                                
                                                           (% of whole study group)                                            
  -------------------------------------------------------- ------------------------------------------------------- ----------- ------------
  **Patients' self-reports, n (% of whole study group)**                                                                       

   **No dose missed during the last week**                 145 (67.8)                                              25 (11.7)   170 (79.4)

   **One or more doses missed during the last week**       17 (7.9)                                                27 (12.6)   44 (20.6)

                                                                                                                               

                                                           162 (75.7)[a](#tfn4-ppa-11-1897){ref-type="table-fn"}   52 (24.3)   214 (100)
  -----------------------------------------------------------------------------------------------------------------------------------------

**Note:**

One patient's data was missing.

###### 

Patient-, HIV-, and ART-related factors correlated with "unstable" or "poor adherence"

  Item                                                                           Physicians' adherence assessment   *p*-value                                         
  ------------------------------------------------------------------------------ ---------------------------------- ----------- ----- ---------- ------- ------------ ---------
  Patient-related factors                                                                                                                                             
   Male sex                                                                      132                                82          28    78         12      71           0.479
   Age (years)[a](#tfn6-ppa-11-1897){ref-type="table-fn"}                        48                                 40--55      42    33--51     46      44--48       0.020
    \<30                                                                         10                                 6.2         6     17         1       5.9          0.120
    ≥30                                                                          152                                93.8        30    83         16      94           
   Transmission route                                                                                                                                                 
    MSM                                                                          91                                 56          13    36         4       24           0.007
    Transmission in HPC                                                          17                                 11          7     19         5       29           0.040
    IVDU                                                                         3                                  1.9         8     22         4       24           \<0.001
    Other                                                                        19                                 12          5     14         3       18           0.631
    Unknown                                                                      33                                 20          5     14         1       5.9          0.303
   Comorbidities                                                                                                                                                      
    Psychiatric disorder                                                         40                                 25          15    42         8       47           0.030
    HBV                                                                          7                                  4.3         3     8.3        0       0            0.494
    HCV                                                                          6                                  3.7         6     17         1       5.9          0.013
    Cardiovascular risk factors                                                  41                                 25          8     22         2       12           0.527
    Major vascular event                                                         9                                  5.6         1     2.8        1       5.9          0.758
    Other                                                                        89                                 55          13    36         6       35           0.052
   Co-medication                                                                                                                                                      
    Psychiatric                                                                  17                                 11          6     17         1       5.9          0.514
    Cardiovascular                                                               41                                 25          8     22         1       5.9          0.226
    Antiinfectives                                                               9                                  5.6         6     17         1       5.9          0.079
    Other                                                                        35                                 22          10    28         3       18           0.687
  HIV-related factors                                                                                                                                                 
   Time since HIV diagnosis (years)[a](#tfn6-ppa-11-1897){ref-type="table-fn"}   9                                  4--16       10    5--21      19      15--21       0.002
    \<1                                                                          6                                  3.8         1     2.9        0       0            0.024
    1--10                                                                        89                                 56          17    49         3       17           
    \>10                                                                         65                                 41          17    49         14      82           
   History of AIDS                                                               11                                 6.8         9     25         4       24           0.002
   HIV-1 RNA VL (cp/mL)[a](#tfn6-ppa-11-1897){ref-type="table-fn"}               19                                 19--39      49    19--49     4,824   60--17,542   \<0.001
   CD4 cell count (n/μL)a                                                        680                                487--887    503   211--761   315     86--426      \<0.001
  ART-related factors                                                                                                                                                 
   ART duration (years)[a](#tfn6-ppa-11-1897){ref-type="table-fn"}               6                                  3--12       5     3--11      14      9--17        0.022
    \<1                                                                          10                                 6.3         3     8.6        0       0            0.142
    1--10                                                                        103                                64          23    66         7       41           
    \>10                                                                         47                                 29          9     26         10      59           
   ART dosing and pill burden                                                                                                                                         
    STR                                                                          50                                 31          13    36         2       12           0.173
    MTR once daily                                                               78                                 48          16    44         9       53           0.841
    MTR twice daily                                                              34                                 21          7     19         6       35           0.373
   Current ART regimen                                                                                                                                                
    NRTI containing                                                              143                                88          34    94         15      88           0.629
    NNRTI containing                                                             79                                 49          10    28         1       5.9          \<0.001
    PI containing                                                                46                                 28          17    47         12      71           0.001
    CCR5 containing                                                              2                                  1.2         0     0          0       0            1
    INI containing                                                               52                                 32          11    31         6       35           0.936

**Note:** *p*-values were calculated using the Fisher's extended exact and Kruskal--Wallis test.

Data presented as median and IQR.

**Abbreviations:** AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; CCR5, C-C chemokine receptor 5 inhibitor; cp, copies; HBV, chronic hepatitis B infection; HCV, chronic hepatitis C infection; HIV, human immunodeficiency virus; HPC, high prevalence country; IQR, interquartile range; INI, integrase inhibitor; IVDU, intravenous drug use; MSM, men having sex with men; MTR, multi-tablet regimen; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STR, single-tablet regimen; VL, viral load.

###### 

Association of patient dissatisfaction with ART and nonadherence

  Patient dissatisfaction regarding   Physicians' adherence assessment   *p*-value                         
  ----------------------------------- ---------------------------------- ----------- --- ------ --- ------ -------
  Interference with daily routine     16                                 9.9         9   25.0   6   35.3   0.003
  Efficacy                            3                                  1.9         4   11.1   1   5.9    0.001
  Simplicity                          6                                  3.7         6   16.7   2   11.8   0.018
  Side effects                        26                                 16.0        9   25.0   6   35.0   0.218

**Abbreviation:** ART, antiretroviral therapy.
